Nova Eye Medical (EYE) Discussion, page-14

First 14 Last

Share
Profile

Follow
hatmopit

7,130 Posts.

1070

11/03/23

20:39

Post #: 66716285
Share
Originally posted by TreasureHunterr: ↑

Great analysis!

Clearly iTrack Advance is now the superior option for canaloplasty. This should be reflected by a significant increase in revenue once it is cleared by the FDA (which could happen as early as next week)

It is important to note as well the difference between canaloplasty (iTrack) and stent based procedures. At the moment, the vast majority of operations are performed using stents or shunts (think iStent by Glaukos, or the Hydrus device). These have always been quick and easy (and quite effective) however there are still a number of important flaws which could drive a shift from these procedures to canaloplasty. A stent is literally a small piece of metal that is inserted in the eye and left there, thereby (unnaturally) unblocking the canal and relieving pressure. There are several issues with this type of procedure:

It is difficult to determine where the blockage is, meaning stents are often incorrectly placed. This requires that they are removed (a long procedure in itself) and reinserted (again, a further annoyance for patients). This is not an issue for iTrack as it treats ALL points of resistance!
There are also typically multiple locations causing IOP issues, meaning that whilst a stent may relieve one source of the elevated IOP, it can fail to target all potential points of resistance (canaloplasty targets all points of resistance)
The idea of leaving a stent in your eye is often daunting for many patients, whereas canaloplasty leaves nothing behind and is naturally reducing IOP.
Stents have a higher risk of bleeding as well as causing more endothelial cell loss compared to canaloplasty.
Recent changes to the CPT codes in the US for canaloplasty and stents means that canaloplasty is a cheaper procedure, making it more appealing to Drs and patients especially as the cost of living continues to rise.

Also note the fact that Drs are increasingly combining canaloplasty and stents which could present a huge opportunity for iTrack Advance to really accelerate sales growth (could also lead to increased M&A activity in the space)

Expand

Good quality research & discussion thanks.

Obviously some market share to possibly be won, well in Canaloplasty anyway. Plenty of other MIGS options out there, choice of which seems to depend on many things, including the skill of the surgeon so if iTrack advanced is 'simple/easy' to use it will become a part of the surgeons tools kit sooner. I hope marketing is great & that uptake is fast & significant ..... & so we wait .....

Interesting article & summery here:

https://eyesoneyecare.com/resources/heres-when-and-why-i-use-each-of-these-migs-devices/

.
EYE Price at posting: 20.0¢ Sentiment: Hold Disclosure: Held
5 Upvote

0 Great analysis

Reply